TT Factor - Company Presentation

569 views

Published on

A brief description of our goals and mission inside of the IFOM and IEO Oncology Research Campus philosophy

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
569
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

TT Factor - Company Presentation

  1. 1. Media&ng  rela&ons  with  industry   Company  presenta&on   July  2011  
  2. 2. FOCUSING  THE  MODEL  IFOM   and   IEO   joined   forces   to   create   in   June   2010   a  tech   transfer   opera-on   which   could   also   support  business   development   for   drug   discovery   and   other  transla&onal  programs  
  3. 3. IFOM  and  IEO  at  glance  •  The   IFOM-­‐IEO   Campus   is   one   of   Europe’s   largest   research   campus   dedicated   to   Cancer   Research   with   over   400   scien&sts   and   4   PhD   programs   with   150   PhD   students;  •  The  IEO  is  a  private  research  hospital  with  320  MD  and   PhDs   dedicated   to   preven&on,   early   diagnosis   and   therapy   of   cancer   through   advanced   technology   and   medical  prac&ces;  •  Since  mid  2009,  IEO  has  started  an  industry   standard  drug  discovery  program  (DDP);  
  4. 4. TTFactor    MISSION  Help   IFOM   and   IEO   improving   and   increasing   solu7ons   to  medical  needs  of  pa7ents  while  funding  their  research  Advance   scien7fic   results   arising   from   the   IFOM   and   IEO   by  suppor7ng   the   genera7on,   protec7on   and   transfer   of  intellectual  proper7es  and  know  how  to  the  for  profit  sector  through:   – Technology  licensing  (Confiden7ality  Ag.,  Term  sheet,  Due  diligence);   – Sponsored  research  agreements;     – MTA  (Material  transfer  Agreements);   – and  spin  off  crea7on.  
  5. 5. TEAM  Daniela Bellomo PhD MBA General ManagementMario Cesana MSc (Econ) Chief Financial OfficerGermano Ferrari PhD MBA Business DevelopmentMarzia Fumagalli PhD Intellectual PropertyMarilina Palmiotto LLP LegalJacopo Franchini BSc Business Development AssociateAurelia Ramunni Assistant Pier Giuseppe Pelicci, President - IEO Claudio Basilico - New York University Andrea Cuomo - ST Microelectronics Marco Foiani - IFOMBOARD  OF     Isaac Kohlberg - Harvard UniversityDIRECTORS   Tomas Lindhal - FRS-Cancer Research UK Stefano Michelini - IEO Elisabetta Petrucci - FIRC Domenico Triarico - IEO Raffaela Zoboli - IFOM
  6. 6. ACTIVITIES   FOCUSED TOWARDS FOCUSED TOWARDS EXTERNAL INTERNAL STAKEHOLDERS STAKEHOLDERSPATENTING EDUCATIONAL CAMPAIGN ON IPMARKETING SUPPORT INTERNALLICENSING OFFICES IN IP ISSUESSPONSORED RESEARCH BUSINESSSPINOFFS DEVELOPMENT FOR DDP
  7. 7. PATENT  PORTFOFLIO  AVAILABLE  FOR   LICENSING   Please visit our web site www.ttfactor.com to look for new patent opportunities Subject   Inves-gators   Filed   Descrip-on  Biomarkers   Pier  Paolo  Di  Fiore  at  al.   2004   A  novel  cancer  “signature”  (10  genes  or  80  genes)  which  helps  to  predict   the  course  of  disease  and  the  choice  of  treatment  in  early  stages  of  Lung   Cancer  Biomarkers   Pier  Paolo  Di  Fiore  at  al.   2005   Method   for   establishing   suscep&bility   to   drug   treatment   in   breast   cancer   for  drugs  ac&ng  on  Numb  gene  (GRANTED  IN  USA)  Small  Molecules   Peter  De  Wulf  et  al.   2009   Novel  an&-­‐cancer  compounds  with  an&tubulin  effect  Small  Molecules   Saverio  Minucci  et  al.   2010   Novel  compounds  with  an&-­‐tumor  effect  inhibi&ng  LSD1  and  LSD2  histone   demethylases  for  the  treatment  of  tumors  and  viral  infec&ons  Tumor  Immunotherapy   Maria  Rescigno  et  al.   2010   Method  to  improve  the  tumoral  an&gen  presenta&on  to  dendri&c  cells  by   Salmonella  infec&on  for  melanoma  therapy  or  prophylaxis  Screening  Assay   Ario  De  Marco  et  al.   2010   Assay  for  iden&fying  agents  ac&ng  on  cell  growth  (through  eIF6)  Biologics   Nicolai  Sidenius   2010   A  novel  “dual  ac&on”  type  of  inhibitor  of  the  urokinase-­‐type  plasminogen   ac&vator  receptor  (uPAR)  Biomarkers   Pier  Paolo  Di  Fiore  at  al.   2010   A  serum  circula&ng  miRNAs  diagnos&c  test  to  iden&fy  asymptoma&c  high-­‐ risk  individuals  with  early  stages  lung  cancer  (NSCLC)  Diagnos-cs   Marco  Chinol  et  al.   2010   Novel  radiopharmaceu&cals  with  an  extended  half-­‐life  for  cancer  diagnosis   and  therapy  
  8. 8. Visit  us  at  www.cactor.com     Contact us at TTFactor s.r.l. Via Adamello, 16 20139 Milano T: +39 02 94375140 F +39 02 94375991 e-mail: info@ttfactor.com

×